Balaxi Pharmaceuticals Limited is listed on the NSE. Auto-imported from the NSE equity master; profile pending.
1,903 historical price candles were omitted because the exchange source has not been verified.
No positive flags triggered.
Structured signal from quality, growth, valuation and momentum.
₹ crore, by fiscal year
% of revenue, by fiscal year
Comparable companies from the narrowest available industry classification.
Reported profit and loss, balance sheet, cash flow and growth history.
Annual operating, return, leverage and working-capital ratios.
Current futures and options contracts with compact option-chain pages.
Mutual-fund schemes that disclosed a holding in the company.
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Upcoming dates and the company’s corporate-action history.
Latest exchange announcements, filings and downloadable documents.
Annual reports, earnings call transcripts and presentations will appear here once ingested.
Consolidated figures
| Ratio | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Margins | |||||
| Gross margin % | 30% | 39.8% | 46.7% | 43.4% | 44.2% |
| EBITDA margin % | 18% | 16.8% | 19.4% | 12.7% | 3.2% |
| EBIT margin % | 17.8% | 16.3% | 18.5% | 12.1% | 2.4% |
| PAT margin % | 17.1% | 13.7% | -1% | 8.6% | 0.5% |
| Working capital | |||||
| Receivable days | — | 58 | 84 | 138 | 184 |
| Inventory days | — | 189 | 233 | 173 | 202 |
| Payable days | — | 66 | 82 | 36 | 51 |
| NWC days | — | 182 | 235 | 275 | 335 |
| Leverage | |||||
| Current ratio | — | 3.64 | 3.88 | 4.45 | 4.04 |
| Debt to EBITDA | — | 0.21 | 0.38 | 1.39 | 6.55 |
| Debt to equity | — | 0.06 | 0.09 | 0.22 | 0.22 |
| Interest coverage | 390.4 | 114.8 | 25 | 10.8 | 2.4 |
| Asset turnover | — | 1.4 | 0.93 | 0.94 | 0.8 |
| Return ratios | |||||
| Return on assets % | — | 19.2% | -0.9% | 8.1% | 0.4% |
| Return on capital employed % | — | 30.8% | 21.5% | 13.7% | 3.5% |
| Return on equity % | — | 25.1% | -1.2% | 10.8% | 0.6% |
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
Quarterly shareholding records haven't been ingested for this company.
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
No scheme among the 32 fund houses on record reported a position in Balaxi Pharmaceuticals Limited. Portfolios are published monthly by each AMC; coverage is still partial.
| Company | Mkt Cap | EV | Revenue | EBITDA | OPM | PAT | NPM | ROCE | ROE | WC Days |
|---|---|---|---|---|---|---|---|---|---|---|
| A-One Steels India LimitedAONESTEELSAONESTEELS | ₹3,198 Cr | ₹4,209 Cr | ₹4,149 Cr | ₹285 Cr | 6.9% | ₹126 Cr | 3.1% | 19.3% | 16.5% | — |
| Anawil Wire And Engineering LimitedANAWILANAWIL | ₹1,064 Cr | — | — | — | — | — | — | — | — | — |
| Credent Connect N Care LimitedCREDENTCREDENT | ₹696 Cr | — | — | — | — | — | — | — | — | — |
| Metalic Technoforge LimitedMETALICMETALIC | ₹426 Cr | — | — | — | — | — | — | — | — | — |
| Optimystix Entertainment India LimitedOPTIMYSTIXOPTIMYSTIX | ₹307 Cr | — | — | — | — | — | — | — | — | — |
| Pramodini Medicare LimitedPRAMODINIPRAMODINI | ₹254 Cr | ₹271 Cr | ₹62 Cr | — | — | ₹17 Cr | 27.9% | -11.3% | 39.1% | — |
| Annapurna Swadisht LimitedANNAPURNAANNAPURNA | ₹211 Cr | — | ₹520 Cr | ₹72 Cr | 13.9% | ₹32 Cr | 6.2% | — | — | — |
| Fascinate Textiles LimitedFASCINATEFASCINATE | ₹102 Cr | — | — | — | — | — | — | — | — | — |
| Propshop Events And Exhibitions LimitedPROPSHOPPROPSHOP | ₹97 Cr | — | ₹70 Cr | ₹11 Cr | 15.8% | ₹8 Cr | 11.4% | — | — | — |
| Vinod Texworld LimitedVINODVINOD | ₹82 Cr | — | — | — | — | — | — | — | — | — |
| Skytech Infinite Platform LimitedSKYTECHSKYTECH | ₹38 Cr | ₹44 Cr | — | — | — | — | — | — | — | — |
| Dhansa Labs LimitedDHANSADHANSA | — | — | ₹142 Cr | ₹11 Cr | 7.7% | ₹6 Cr | 3.9% | — | — | — |
Consolidated figures · ₹ crore
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 279 | 336 | 241 | 293 | 270 | |
| COGS | 196 | 202 | 129 | 166 | 151 |
| Gross profit | 84 | 134 | 113 | 127 | 119 |
| 34 | 77 | 66 | 90 | 111 | |
| 50 | 57 | 47 | 37 | 9 | |
| OPM % | 18% | 16.8% | 19.4% | 12.7% | 3.2% |
| Depreciation | 1 | 2 | 2 | 2 | 2 |
| Interest | 0 | 1 | 2 | 3 | 4 |
| 5 | 3 | -41 | -4 | 3 | |
| Profit before tax | 55 | 57 | 2 | 29 | 5 |
| Tax | 7 | 11 | 4 | 4 | 4 |
| Tax % | 12.6% | 19.3% | 217.8% | 12.6% | 73.4% |
| 48 | 46 | -2 | 25 | 1 | |
| PAT margin % | 17.1% | 13.7% | -1% | 8.6% | 0.5% |
| EPS (₹) | 47.7 | 45.8 | -2.3 | 4.5 | 0.3 |
| EPS adjusted (₹) | — | 9 | -0.4 | 4.5 | 0.3 |
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 10 | 11 | 11 | 11 |
| Reserves | 173 | 190 | 221 | 238 |
| Minority interest | — | — | 0 | 0 |
| 12 | 18 | 52 | 56 | |
| 45 | 39 | 27 | 32 | |
| Total equity & liabilities | 240 | 258 | 310 | 337 |
| 41 | 41 | 41 | 82 | |
| CWIP | 3 | 2 | 22 | — |
| Investments | 0 | 0 | 0 | 0 |
| 195 | 215 | 247 | 255 | |
| Total assets | 240 | 258 | 310 | 337 |
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 34 | 6 | 5 | -35 | -5 | |
| -28 | -11 | -1 | -22 | -21 | |
| -0 | 26 | 30 | 34 | 0 | |
| Net cash flow | 6 | 21 | 34 | -23 | -25 |
| Free cash flow | 29 | -5 | 4 | -36 | -19 |
| CFO / Operating profit % | 68% | 10.8% | 10.4% | -94.1% | -52.8% |